BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36151863)

  • 1. Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.
    Rhee J; Birmann BM; De Roos AJ; Epstein MM; Martinez-Maza O; Breen EC; Magpantay LI; Levin LI; Visvanathan K; Hosgood HD; Rohan TE; Smoller SW; Bassig BA; Qi L; Shu XO; Koh WP; Zheng W; Yuan JM; Weinstein SJ; Albanes D; Lan Q; Rothman N; Purdue MP
    Int J Cancer; 2023 Mar; 152(5):865-878. PubMed ID: 36151863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.
    Purdue MP; Lan Q; Langseth H; Grimsrud TK; Hildesheim A; Rothman N
    Int J Cancer; 2020 Jun; 146(12):3312-3319. PubMed ID: 31523805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development.
    Saberi Hosnijeh F; Kolijn PM; Casabonne D; Nieters A; Solans M; Naudin S; Ferrari P; Mckay JD; Weiderpass E; Perduca V; Besson C; Mancini FR; Masala G; Krogh V; Ricceri F; Huerta JM; Petrova D; Sala N; Trichopoulou A; Karakatsani A; La Vecchia C; Kaaks R; Canzian F; Aune D; Boeing H; Schulze MB; Perez-Cornago A; Langerak AW; van der Velden VHJ; Vermeulen R
    Sci Rep; 2020 Aug; 10(1):13814. PubMed ID: 32796953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes.
    Levin LI; Ramirez CM; Liao EL; Guo H; Kim BK; Marrogi AJ; Magpantay LI; Breen EC; Martínez-Maza O
    Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):233-241. PubMed ID: 36409490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occupation and Risk of Non-Hodgkin Lymphoma and Its Subtypes: A Pooled Analysis from the InterLymph Consortium.
    't Mannetje A; De Roos AJ; Boffetta P; Vermeulen R; Benke G; Fritschi L; Brennan P; Foretova L; Maynadié M; Becker N; Nieters A; Staines A; Campagna M; Chiu B; Clavel J; de Sanjose S; Hartge P; Holly EA; Bracci P; Linet MS; Monnereau A; Orsi L; Purdue MP; Rothman N; Lan Q; Kane E; Costantini AS; Miligi L; Spinelli JJ; Zheng T; Cocco P; Kricker A
    Environ Health Perspect; 2016 Apr; 124(4):396-405. PubMed ID: 26340796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes.
    Morton LM; Wang SS; Cozen W; Linet MS; Chatterjee N; Davis S; Severson RK; Colt JS; Vasef MA; Rothman N; Blair A; Bernstein L; Cross AJ; De Roos AJ; Engels EA; Hein DW; Hill DA; Kelemen LE; Lim U; Lynch CF; Schenk M; Wacholder S; Ward MH; Hoar Zahm S; Chanock SJ; Cerhan JR; Hartge P
    Blood; 2008 Dec; 112(13):5150-60. PubMed ID: 18796628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan.
    Pei SN; Wang MC; Ma MC; Kuo CY; Liao CK; Qiu H; Rothwell LA; Liu Y
    Sci Rep; 2021 May; 11(1):10069. PubMed ID: 33980914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insecticide use and risk of non-Hodgkin lymphoma subtypes: A subset meta-analysis of the North American Pooled Project.
    Kachuri L; Beane Freeman LE; Spinelli JJ; Blair A; Pahwa M; Koutros S; Hoar Zahm S; Cantor KP; Weisenburger DD; Pahwa P; Dosman JA; McLaughlin JR; Demers PA; Harris SA
    Int J Cancer; 2020 Dec; 147(12):3370-3383. PubMed ID: 32574374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype.
    Abuamsha H; Kadri AN; Hernandez AV
    Hematol Oncol; 2019 Aug; 37(3):261-269. PubMed ID: 30916804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study.
    Kleinstern G; Camp NJ; Berndt SI; Birmann BM; Nieters A; Bracci PM; McKay JD; Ghesquières H; Lan Q; Hjalgrim H; Benavente Y; Monnereau A; Wang SS; Zhang Y; Purdue MP; Zeleniuch-Jacquotte A; Giles GG; Vermeulen R; Cocco P; Albanes D; Teras LR; Brooks-Wilson AR; Vajdic CM; Kane E; Caporaso NE; Smedby KE; Salles G; Vijai J; Chanock SJ; Skibola CF; Rothman N; Slager SL; Cerhan JR
    Cancer Epidemiol Biomarkers Prev; 2020 May; 29(5):1074-1078. PubMed ID: 32108027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
    Morton LM; Curtis RE; Linet MS; Bluhm EC; Tucker MA; Caporaso N; Ries LA; Fraumeni JF
    J Clin Oncol; 2010 Nov; 28(33):4935-44. PubMed ID: 20940199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Evaluation of Medical Conditions Associated with Risk of Non-Hodgkin Lymphoma using Medicare Claims ("MedWAS").
    Engels EA; Parsons R; Besson C; Morton LM; Enewold L; Ricker W; Yanik EL; Arem H; Austin AA; Pfeiffer RM
    Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1105-13. PubMed ID: 27197296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk.
    Purdue MP; Lan Q; Hoffman-Bolton J; Hildesheim A; Callahan CL; Strickland P; Visvanathan K; Rothman N
    Int J Cancer; 2019 Apr; 144(8):1780-1785. PubMed ID: 30230539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma.
    Pizzi M; Trentin L; Visentin A; Saraggi D; Martini V; Guzzardo V; Righi S; Frezzato F; Piazza F; Sabattini E; Semenzato G; Rugge M
    Hum Pathol; 2019 Mar; 85():251-259. PubMed ID: 30458196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies.
    Makgoeng SB; Bolanos RS; Jeon CY; Weiss RE; Arah OA; Breen EC; Martínez-Maza O; Hussain SK
    JNCI Cancer Spectr; 2018 Dec; 2(4):pky082. PubMed ID: 30873511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses.
    Hosnijeh FS; Portengen L; Späth F; Bergdahl IA; Melin B; Mattiello A; Masala G; Sacerdote C; Naccarati A; Krogh V; Tumino R; Chadeau-Hyam M; Vineis P; Vermeulen R
    Int J Cancer; 2016 May; 138(10):2357-67. PubMed ID: 26684261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort.
    Conroy SM; Maskarinec G; Morimoto Y; Franke AA; Cooney RV; Wilkens LR; Goodman MT; Hernadez BY; Le Marchand L; Henderson BE; Kolonel LN
    Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):337-47. PubMed ID: 23300021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between ambient ultraviolet radiation and non-Hodgkin lymphoma subtypes: a U.S. population-based study of racial and ethnic groups.
    Cahoon EK; Pfeiffer RM; Wheeler DC; Arhancet J; Lin SW; Alexander BH; Linet MS; Freedman DM
    Int J Cancer; 2015 Mar; 136(5):E432-41. PubMed ID: 25258118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.